Cowen & Co. Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Ultragenyx Pharmaceutical (RAREResearch Report) today and set a price target of $62.00. The company’s shares closed last Monday at $38.85, close to its 52-week low of $35.41.

According to, Werber is a 5-star analyst with an average return of 15.2% and a 67.1% success rate. Werber covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Rocket Pharmaceuticals, and Orchard Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $75.57 average price target.

See today’s analyst top recommended stocks >>

Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $113 million. In comparison, last year the company had a GAAP net loss of $87.31 million.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RARE in relation to earlier this year. Most recently, in September 2019, Shalini Sharp, the CFO & EVP of RARE bought 31,843 shares for a total of $176,317.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.